PET imaging of brain amyloid in dementia: a review - PubMed (original) (raw)
Review
doi: 10.1002/gps.2640. Epub 2010 Dec 28.
Affiliations
- PMID: 21905095
- DOI: 10.1002/gps.2640
Review
PET imaging of brain amyloid in dementia: a review
Harriet Quigley et al. Int J Geriatr Psychiatry. 2011 Oct.
Abstract
Objective: To review the rapidly expanding literature of amyloid PET imaging with particular attention to Pittsburgh compound-B (PIB) in Alzheimer's disease (AD), dementia with Lewy bodies (DLB), fronto-temporal dementia (FTD), mild cognitive impairment (MCI) and cognitively normal volunteers.
Design: Literature searches were performed using Medline up to February 2010. Individual articles were then examined for additional references not revealed by automated searches. This yielded 79 articles whose abstracts were read by the authors to select key papers.
Results: Amyloid deposition assessed using PIB-PET is significantly elevated in AD and DLB compared to controls and those with FTD. In MCI, uptake is often intermediate between AD and normal ageing, and excessive amyloid burden in non-demented individuals with MCI are likely to represent high-risk cases. Amyloid deposition appears to be an early event, and as dementia progresses clinical decline seems to be more associated with neurodegeneration than amyloid burden.
Conclusions: PIB-PET imaging is a sensitive and specific marker for underlying Aβ amyloid deposition and represents an important investigative tool for examining the relationship between amyloid burden, clinical symptoms and structural and functional changes in dementia. Amyloid imaging may also be useful for selecting patients for anti-amyloid therapies. However, studies have identified PIB-positive cases in otherwise healthy older individuals (10-30%), limiting diagnostic specificity. Development of biomarkers for investigating other aspects of dementia pathology, i.e. soluble Aβ, tau, synuclein and brain inflammation would further inform our understanding and assist in studying disease-modifying and preventive treatments in dementia.
Copyright © 2010 John Wiley & Sons, Ltd.
Similar articles
- Imaging beta-amyloid burden in aging and dementia.
Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O'Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL. Rowe CC, et al. Neurology. 2007 May 15;68(20):1718-25. doi: 10.1212/01.wnl.0000261919.22630.ea. Neurology. 2007. PMID: 17502554 - In vitro characterization of Pittsburgh compound-B binding to Lewy bodies.
Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, Leone L, Perez K, Cortés M, Culvenor JG, Li QX, Laughton KM, Rowe CC, Masters CL, Cappai R, Villemagne VL. Fodero-Tavoletti MT, et al. J Neurosci. 2007 Sep 26;27(39):10365-71. doi: 10.1523/JNEUROSCI.0630-07.2007. J Neurosci. 2007. PMID: 17898208 Free PMC article. - AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies.
Kantarci K, Lowe VJ, Boeve BF, Senjem ML, Tosakulwong N, Lesnick TG, Spychalla AJ, Gunter JL, Fields JA, Graff-Radford J, Ferman TJ, Jones DT, Murray ME, Knopman DS, Jack CR Jr, Petersen RC. Kantarci K, et al. Ann Neurol. 2017 Jan;81(1):58-67. doi: 10.1002/ana.24825. Epub 2016 Dec 19. Ann Neurol. 2017. PMID: 27863444 Free PMC article. - Long night's journey into the day: amyloid-β imaging in Alzheimer's disease.
Villemagne VL, Rowe CC. Villemagne VL, et al. J Alzheimers Dis. 2013;33 Suppl 1:S349-59. doi: 10.3233/JAD-2012-129034. J Alzheimers Dis. 2013. PMID: 22710919 Review. - Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo.
Rabinovici GD, Jagust WJ. Rabinovici GD, et al. Behav Neurol. 2009;21(1):117-28. doi: 10.3233/BEN-2009-0232. Behav Neurol. 2009. PMID: 19847050 Free PMC article. Review.
Cited by
- Blood Markers Show Neural Consequences of LongCOVID-19.
Tang N, Kido T, Shi J, McCafferty E, Ford JM, Dal Bon K, Pulliam L. Tang N, et al. Cells. 2024 Mar 8;13(6):478. doi: 10.3390/cells13060478. Cells. 2024. PMID: 38534322 Free PMC article. - Examining the diagnostic value of the mnemonic discrimination task for classification of cognitive status and amyloid-beta burden.
Kim S, Adams JN, Chappel-Farley MG, Keator D, Janecek J, Taylor L, Mikhail A, Hollearn M, McMillan L, Rapp P, Yassa MA. Kim S, et al. Neuropsychologia. 2023 Dec 15;191:108727. doi: 10.1016/j.neuropsychologia.2023.108727. Epub 2023 Nov 7. Neuropsychologia. 2023. PMID: 37939874 Free PMC article. - Multi-domain cognition dysfunction accompanies frontoparietal and temporal amyloid accumulation in the elderly.
Wang D, Xu K, Dang M, Sang F, Chen K, Zhang Z, Li X. Wang D, et al. Cereb Cortex. 2023 Nov 27;33(23):11329-11338. doi: 10.1093/cercor/bhad369. Cereb Cortex. 2023. PMID: 37859548 Free PMC article. - The Role of Clinical Assessment in the Era of Biomarkers.
Carlos AF, Josephs KA. Carlos AF, et al. Neurotherapeutics. 2023 Jul;20(4):1001-1018. doi: 10.1007/s13311-023-01410-3. Epub 2023 Aug 18. Neurotherapeutics. 2023. PMID: 37594658 Free PMC article. Review. - The Future of Precision Medicine in the Cure of Alzheimer's Disease.
Arafah A, Khatoon S, Rasool I, Khan A, Rather MA, Abujabal KA, Faqih YAH, Rashid H, Rashid SM, Bilal Ahmad S, Alexiou A, Rehman MU. Arafah A, et al. Biomedicines. 2023 Jan 25;11(2):335. doi: 10.3390/biomedicines11020335. Biomedicines. 2023. PMID: 36830872 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical